KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Short term Debt (2017 - 2025)

Historic Short term Debt for BeOne Medicines (ONC) over the last 10 years, with Q3 2025 value amounting to $813.3 million.

  • BeOne Medicines' Short term Debt fell 584.71% to $813.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $813.3 million, marking a year-over-year decrease of 584.71%. This contributed to the annual value of $851.5 million for FY2024, which is 2370.29% up from last year.
  • Per BeOne Medicines' latest filing, its Short term Debt stood at $813.3 million for Q3 2025, which was down 584.71% from $808.4 million recorded in Q2 2025.
  • BeOne Medicines' 5-year Short term Debt high stood at $863.8 million for Q3 2024, and its period low was $281.8 million during Q1 2023.
  • Over the past 5 years, BeOne Medicines' median Short term Debt value was $441.3 million (recorded in 2022), while the average stood at $565.0 million.
  • Its Short term Debt has fluctuated over the past 5 years, first soared by 348510.36% in 2021, then plummeted by 3082.55% in 2023.
  • Over the past 5 years, BeOne Medicines' Short term Debt (Quarter) stood at $427.6 million in 2021, then plummeted by 30.33% to $297.9 million in 2022, then surged by 131.1% to $688.4 million in 2023, then grew by 23.7% to $851.5 million in 2024, then decreased by 4.49% to $813.3 million in 2025.
  • Its last three reported values are $813.3 million in Q3 2025, $808.4 million for Q2 2025, and $763.5 million during Q1 2025.